Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2017 Summary Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory autoreceptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Oncology which include indications Depression, Parkinson's Disease, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Chronic Pain, Cognitive Impairment, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Glioma, Schizophrenia and Treatment Resistant Depression. Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects - The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview 6 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 10 Products under Development by Universities/Institutes 12 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment 14 Assessment by Mechanism of Action 14 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development 18 Addex Therapeutics Ltd 18 Aevi Genomic Medicine Inc 18 Denovo Biopharma LLC 19 Domain Therapeutics SA 19 Eli Lilly and Company 20 Prexton Therapeutics SA 20 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles 21 DT-010991 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 DT-011088 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 fasoracetam - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 LY-2969822 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 LY-3020371 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 LY-341495 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 pomaglumetad methionil - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Agonize mGluR3 for Parkinson's Disease - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecules to Modulate mGlu3 Receptor for CNS Disorders - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 VU-0092273 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 VU-0650786 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products 35 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products 37 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones 38 Featured News & Press Releases 38 May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 38 Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 38 Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 40 Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 40 Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome 41 Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents 42 Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder 42 Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD 43 Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson's disease with renewed support by The Michael J. Fox Foundation 44 Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 44 Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 45 Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research 45 Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indication, H2 2017 9 Number of Products under Development by Companies, H2 2017 10 Products under Development by Companies, H2 2017 11 Number of Products under Investigation by Universities/Institutes, H2 2017 12 Products under Investigation by Universities/Institutes, H2 2017 13 Number of Products by Stage and Mechanism of Actions, H2 2017 15 Number of Products by Stage and Route of Administration, H2 2017 16 Number of Products by Stage and Molecule Type, H2 2017 17 Pipeline by Addex Therapeutics Ltd, H2 2017 18 Pipeline by Aevi Genomic Medicine Inc, H2 2017 18 Pipeline by Denovo Biopharma LLC, H2 2017 19 Pipeline by Domain Therapeutics SA, H2 2017 19 Pipeline by Eli Lilly and Company, H2 2017 20 Pipeline by Prexton Therapeutics SA, H2 2017 20 Dormant Products, H2 2017 35 Dormant Products, H2 2017 (Contd..1), H2 2017 36 Discontinued Products, H2 2017 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
